返回 Agenda
Session Chair(s)
John Scott, PHD, MA
Division Director, Office of Biostatistics, CBER
FDA, United States
Speaker(s)
Qi Jiang, PHD
Amgen Inc., United States
Executive Director, Global Biostatistical Science
Benefit-risk Assessment Across the Lifecycle of Products: Methods and Challenges
Chunlei Ke, PHD
Amgen Inc., United States
Evaluation of Benefit and Risk
Ellis Unger, MD
Hyman, Phelps & McNamara, P.C., United States
Principal Drug Regulatory Expert
Carmen Bozic, MD, PHD
Biogen, United States
SVP, Portfolio Transformation
Panelist
Thomas J. Permutt, PHD
FDA, United States
Associate Director for Statistical Science and Policy, OB, OTS, CDER